Lancet Oncology Commission Identifies Global Disparities in Cancer Genomics and Precision Oncology Access
The Lancet Oncology Commission on Cancer Genomics and Precision Oncology has released a comprehensive report detailing significant global inequalities in the delivery of high-quality cancer care. The Commission, launched at the World Cancer Congress in Hong Kong, found that advanced molecular testing and precision oncology treatments are primarily accessible in wealthy countries and well-resourced areas. This disparity means that a large majority of eligible cancer patients worldwide, estimated at 7–8 million annually, do not receive the necessary biomarker testing to guide their diagnosis or treatment. The research and data ecosystems supporting precision oncology are also unequal, with genomic research, biomarker-driven clinical trials, and health data disproportionately concentrated in high-income countries and Western populations. The Commission, comprising experts in oncology, genomics, pathology, public health, health policy, economics, data science, ethics, and patient advocacy, has developed a fram...